Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and contine...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Rong, Wang, Yang, Wang, Lili, Deng, Xiaoqian, Huo, Shanshan, Jiang, Shibo, Yu, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/
https://www.ncbi.nlm.nih.gov/pubmed/35038651
http://dx.doi.org/10.1016/j.coviro.2021.12.015
_version_ 1784624265793896448
author Xiang, Rong
Wang, Yang
Wang, Lili
Deng, Xiaoqian
Huo, Shanshan
Jiang, Shibo
Yu, Fei
author_facet Xiang, Rong
Wang, Yang
Wang, Lili
Deng, Xiaoqian
Huo, Shanshan
Jiang, Shibo
Yu, Fei
author_sort Xiang, Rong
collection PubMed
description The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.
format Online
Article
Text
id pubmed-8716168
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-87161682021-12-30 Neutralizing monoclonal antibodies against highly pathogenic coronaviruses Xiang, Rong Wang, Yang Wang, Lili Deng, Xiaoqian Huo, Shanshan Jiang, Shibo Yu, Fei Curr Opin Virol Article The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases. Elsevier B.V. 2022-04 2021-12-30 /pmc/articles/PMC8716168/ /pubmed/35038651 http://dx.doi.org/10.1016/j.coviro.2021.12.015 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Xiang, Rong
Wang, Yang
Wang, Lili
Deng, Xiaoqian
Huo, Shanshan
Jiang, Shibo
Yu, Fei
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title_full Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title_fullStr Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title_full_unstemmed Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title_short Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
title_sort neutralizing monoclonal antibodies against highly pathogenic coronaviruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/
https://www.ncbi.nlm.nih.gov/pubmed/35038651
http://dx.doi.org/10.1016/j.coviro.2021.12.015
work_keys_str_mv AT xiangrong neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT wangyang neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT wanglili neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT dengxiaoqian neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT huoshanshan neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT jiangshibo neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses
AT yufei neutralizingmonoclonalantibodiesagainsthighlypathogeniccoronaviruses

Ejemplares similares